Please provide your email address to receive an email when new articles are posted on . Device-based therapy may be necessary for certain patients with NYHA class II/III heart failure with reduced ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window "Medical ...
Hosted on MSN
NanoPhoria raises $98m to develop HFrEF treatment
Italy-based biotech company NanoPhoria Bioscience has announced the initial closing of its Series A funding round, raising €83.5m ($98m). The round was led by XGEN Venture, Sofinnova Partners and CDP ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback